Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ironwood Pharmaceuticals stock | 11.81

Own Ironwood Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Ironwood Pharmaceuticals, Inc is a drug manufacturers—specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 317 staff and has a trailing 12-month revenue of around USD$426.8 million.

How to buy shares in Ironwood Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ironwood Pharmaceuticals. Find the stock by name or ticker symbol: IRWD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ironwood Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$11.81, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ironwood Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ironwood Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Ironwood Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Ironwood Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$11.81, which is 1.52% up on its pre-crash value of USD$11.63 and 47.81% up on the lowest point reached during the March crash when the shares fell as low as USD$7.99.

If you had bought USD$1,000 worth of Ironwood Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$768.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$944.80.

Ironwood Pharmaceuticals share price

Use our graph to track the performance of IRWD stocks over time.

Ironwood Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$11.81
52-week range USD$7.99 - USD$14.1
50-day moving average USD$9.79
200-day moving average USD$10.0728
Wall St. target price USD$10.5
PE ratio 16.2097
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.615

Buy Ironwood Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ironwood Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ironwood Pharmaceuticals price performance over time

Historical closes compared with the close of $11.81 from 2020-11-16

1 week (2020-11-18) 1.99%
1 month (2020-10-23) 22.51%
3 months (2020-08-25) 11.52%
6 months (2020-05-22) -1.34%
1 year (2019-11-25) -3.20%
2 years (2018-11-23) -9.29%
3 years (2017-11-24) -24.49%
5 years (2015-11-25) -3.67%

Is Ironwood Pharmaceuticals under- or over-valued?

Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ironwood Pharmaceuticals's P/E ratio

Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Ironwood Pharmaceuticals shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ironwood Pharmaceuticals's EBITDA

Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$167.7 million.

The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ironwood Pharmaceuticals financials

Revenue TTM USD$426.8 million
Operating margin TTM 38.03%
Gross profit TTM USD$293 million
Return on assets TTM 26.72%
Return on equity TTM 0%
Profit margin 22.74%
Book value $-1.402
Market capitalisation USD$1.6 billion

TTM: trailing 12 months

Shorting Ironwood Pharmaceuticals shares

There are currently 20.6 million Ironwood Pharmaceuticals shares held short by investors – that's known as Ironwood Pharmaceuticals's "short interest". This figure is 1% down from 20.8 million last month.

There are a few different ways that this level of interest in shorting Ironwood Pharmaceuticals shares can be evaluated.

Ironwood Pharmaceuticals's "short interest ratio" (SIR)

Ironwood Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ironwood Pharmaceuticals shares currently shorted divided by the average quantity of Ironwood Pharmaceuticals shares traded daily (recently around 1.6 million). Ironwood Pharmaceuticals's SIR currently stands at 12.62. In other words for every 100,000 Ironwood Pharmaceuticals shares traded daily on the market, roughly 12620 shares are currently held short.

However Ironwood Pharmaceuticals's short interest can also be evaluated against the total number of Ironwood Pharmaceuticals shares, or, against the total number of tradable Ironwood Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ironwood Pharmaceuticals's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Ironwood Pharmaceuticals shares in existence, roughly 130 shares are currently held short) or 0.2013% of the tradable shares (for every 100,000 tradable Ironwood Pharmaceuticals shares, roughly 201 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ironwood Pharmaceuticals.

Find out more about how you can short Ironwood Pharmaceuticals stock.

Ironwood Pharmaceuticals share dividends

We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.

Have Ironwood Pharmaceuticals's shares ever split?

Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 2 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.

Ironwood Pharmaceuticals share price volatility

Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $7.99 up to $14.1. A popular way to gauge a stock's volatility is its "beta".

IRWD.US volatility(beta: 1.43)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.4346. This would suggest that Ironwood Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ironwood Pharmaceuticals overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site